KR20240087242A - Composition for Prevention or Treatment Respiratory Diseases Comprising Combination Extracts of Sorbus commixta, Hibiscus syriacus and Ulmus macrocarpa as an Active Ingredient - Google Patents
Composition for Prevention or Treatment Respiratory Diseases Comprising Combination Extracts of Sorbus commixta, Hibiscus syriacus and Ulmus macrocarpa as an Active Ingredient Download PDFInfo
- Publication number
- KR20240087242A KR20240087242A KR1020220172745A KR20220172745A KR20240087242A KR 20240087242 A KR20240087242 A KR 20240087242A KR 1020220172745 A KR1020220172745 A KR 1020220172745A KR 20220172745 A KR20220172745 A KR 20220172745A KR 20240087242 A KR20240087242 A KR 20240087242A
- Authority
- KR
- South Korea
- Prior art keywords
- sharon
- rose
- respiratory diseases
- extracts
- rowan
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 119
- 244000130592 Hibiscus syriacus Species 0.000 title claims abstract description 61
- 235000018081 Hibiscus syriacus Nutrition 0.000 title claims abstract description 61
- 208000023504 respiratory system disease Diseases 0.000 title claims abstract description 31
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 238000011282 treatment Methods 0.000 title claims abstract description 18
- 239000004480 active ingredient Substances 0.000 title claims abstract description 12
- 230000002265 prevention Effects 0.000 title claims abstract description 7
- 241001300088 Ulmus macrocarpa Species 0.000 title description 3
- 235000004489 Sorbus commixta Nutrition 0.000 title description 2
- 241001115347 Sorbus commixta Species 0.000 title description 2
- 244000019194 Sorbus aucuparia Species 0.000 claims abstract description 51
- 235000009790 Sorbus aucuparia Nutrition 0.000 claims abstract description 36
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims abstract description 34
- 102000009616 Mucin 5AC Human genes 0.000 claims abstract description 33
- 108010034536 Mucin 5AC Proteins 0.000 claims abstract description 33
- 238000004519 manufacturing process Methods 0.000 claims abstract description 24
- 230000028327 secretion Effects 0.000 claims abstract description 22
- 239000000428 dust Substances 0.000 claims abstract description 21
- 235000013305 food Nutrition 0.000 claims abstract description 18
- 239000003642 reactive oxygen metabolite Substances 0.000 claims abstract description 17
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 16
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 14
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 14
- 210000003097 mucus Anatomy 0.000 claims abstract description 12
- 210000004072 lung Anatomy 0.000 claims abstract description 6
- 230000002000 scavenging effect Effects 0.000 claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 206010011224 Cough Diseases 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 claims description 3
- 208000026435 phlegm Diseases 0.000 claims description 3
- 206010014561 Emphysema Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 201000009267 bronchiectasis Diseases 0.000 claims description 2
- 206010006451 bronchitis Diseases 0.000 claims description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 2
- 241000196324 Embryophyta Species 0.000 abstract description 16
- 235000006414 serbal de cazadores Nutrition 0.000 abstract description 15
- 230000006872 improvement Effects 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 50
- 239000002158 endotoxin Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 238000000034 method Methods 0.000 description 13
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 11
- 230000036541 health Effects 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- PHEDXBVPIONUQT-UHFFFAOYSA-N Cocarcinogen A1 Natural products CCCCCCCCCCCCCC(=O)OC1C(C)C2(O)C3C=C(C)C(=O)C3(O)CC(CO)=CC2C2C1(OC(C)=O)C2(C)C PHEDXBVPIONUQT-UHFFFAOYSA-N 0.000 description 10
- 235000013376 functional food Nutrition 0.000 description 10
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 241001092391 Sorbus Species 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 235000008345 mountainash Nutrition 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 244000042430 Rhodiola rosea Species 0.000 description 4
- 235000003713 Rhodiola rosea Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000003172 expectorant agent Substances 0.000 description 4
- 230000003419 expectorant effect Effects 0.000 description 4
- 239000002085 irritant Substances 0.000 description 4
- 231100000021 irritant Toxicity 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 3
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- NTNWOCRCBQPEKQ-YFKPBYRVSA-N N(omega)-methyl-L-arginine Chemical compound CN=C(N)NCCC[C@H](N)C(O)=O NTNWOCRCBQPEKQ-YFKPBYRVSA-N 0.000 description 3
- NTNWOCRCBQPEKQ-UHFFFAOYSA-N NG-mono-methyl-L-arginine Natural products CN=C(N)NCCCC(N)C(O)=O NTNWOCRCBQPEKQ-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 210000001132 alveolar macrophage Anatomy 0.000 description 3
- 230000000954 anitussive effect Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 229940124584 antitussives Drugs 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940066493 expectorants Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- VQVUBYASAICPFU-UHFFFAOYSA-N (6'-acetyloxy-2',7'-dichloro-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Cl)=C(OC(C)=O)C=C1OC1=C2C=C(Cl)C(OC(=O)C)=C1 VQVUBYASAICPFU-UHFFFAOYSA-N 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 2
- 235000018927 edible plant Nutrition 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000001117 malignant triton tumor Diseases 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 231100000065 noncytotoxic Toxicity 0.000 description 2
- 230000002020 noncytotoxic effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- -1 olive oil Chemical compound 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000013618 particulate matter Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- PXEZTIWVRVSYOK-UHFFFAOYSA-N 2-(3,6-diacetyloxy-2,7-dichloro-9h-xanthen-9-yl)benzoic acid Chemical compound C1=2C=C(Cl)C(OC(=O)C)=CC=2OC2=CC(OC(C)=O)=C(Cl)C=C2C1C1=CC=CC=C1C(O)=O PXEZTIWVRVSYOK-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- BMFMQGXDDJALKQ-BYPYZUCNSA-N Argininic acid Chemical compound NC(N)=NCCC[C@H](O)C(O)=O BMFMQGXDDJALKQ-BYPYZUCNSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 1
- 229940123150 Chelating agent Drugs 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 240000003553 Leptospermum scoparium Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 241000219071 Malvaceae Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 230000010757 Reduction Activity Effects 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 244000197975 Solidago virgaurea Species 0.000 description 1
- 235000000914 Solidago virgaurea Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229920001284 acidic polysaccharide Polymers 0.000 description 1
- 150000004805 acidic polysaccharides Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 1
- 239000000809 air pollutant Substances 0.000 description 1
- 231100001243 air pollutant Toxicity 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229940124748 beta 2 agonist Drugs 0.000 description 1
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 210000000412 mechanoreceptor Anatomy 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 230000000510 mucolytic effect Effects 0.000 description 1
- 229940066491 mucolytics Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 108091008709 muscle spindles Proteins 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 210000001186 vagus nerve Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003135 vibrissae Anatomy 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/314—Foods, ingredients or supplements having a functional effect on health having an effect on lung or respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 마가목, 무궁화 및 유근피의 복합추출물을 유효성분으로 포함하는 호흡기 질환의 예방 및 치료용 조성물에 관한 것이다.
본 발명에 따른 마가목, 무궁화 및 유근피의 3종 식물 복합추출물은 염증 매개인자인 일산화질소 생성을 억제하고, 미세먼지의 흡입에 의해 폐조직에서 유도된 활성산소종 소거 활성을 나타내고, 염증성 점액단백질인 Mucin 5AC(MUC5AC)의 분비를 억제하므로 호흡기 질환의 예방, 개선 및 치료 용도로 식품 및 의약 분야에 유용하게 활용될 수 있다. The present invention relates to a composition for the prevention and treatment of respiratory diseases comprising complex extracts of rowan tree, Rose of Sharon and Radix root bark as active ingredients.
The complex extract of three types of plants of rowan, Rose of Sharon and Rhythmia root according to the present invention suppresses the production of nitric oxide, an inflammatory mediator, exhibits reactive oxygen species scavenging activity induced in lung tissue by inhalation of fine dust, and removes inflammatory mucus protein. Because it inhibits the secretion of Mucin 5AC (MUC5AC), it can be useful in the food and pharmaceutical fields for the prevention, improvement, and treatment of respiratory diseases.
Description
본 발명은 마가목, 무궁화 및 유근피의 복합추출물을 유효성분으로 포함하는 호흡기 질환의 예방 및 치료용 조성물에 관한 것이다.The present invention relates to a composition for the prevention and treatment of respiratory diseases comprising complex extracts of rowan tree, Rose of Sharon and Radix root bark as active ingredients.
우리 몸의 호흡기는 물리 화학적인 자극에 대해 끊임없이 방어하고 있는 기관 중 하나로 자극물질이 호흡기로 유입되면 대부분 자극물질은 코털에 걸려 호흡기로 들어오지 못하나 이를 통과한 미세한 자극물질은 점액으로 둘러싸이고, 기도 벽에 있는 미세한 섬모의 운동으로 위로 또는 밖으로 내보내 지게 되는데, 바로 이것이 기침의 기본 작용원리이다.Our body's respiratory system is one of the organs that constantly defends against physical and chemical stimulation. When irritants enter the respiratory tract, most irritants get caught in the nose hairs and cannot enter the respiratory tract. However, fine irritants that pass through are surrounded by mucus and the airway walls. It is sent up or out through the movement of fine cilia in the body, and this is the basic working principle of coughing.
기침은 기도 점막 자극으로 반사적으로 일어나는 방어기전으로, 지나친 자극에 의한 지속적인 기침이 유발될 경우, 환자의 삶의 질을 경감시키고 악화시키게 된다. 또한, 기침과 같은 원리로 외부에서 먼지나 자극물질 등이 유입되면 우리 몸의 기관지에서는 타액과 함께 근육운동을 해서 외부로 밀어내게 되는데, 이것이 객담(가래) 형성의 원인이며 폐 등 기관지의 염증에 의해서 짙은 화농성 객담이 생기게 된다.Coughing is a defense mechanism that occurs reflexively due to irritation of the airway mucosa. If persistent coughing is caused by excessive stimulation, it reduces and worsens the patient's quality of life. Also, in the same principle as coughing, when dust or irritants come in from the outside, the bronchi of our body use muscle movement together with saliva to push them out. This is the cause of sputum formation and causes inflammation in the bronchi, such as the lungs. This causes thick purulent sputum to form.
결과적으로 찬 공기, 병원성 미생물을 포함한 외부 이물질, 대기 오염 물질, 알레르기 유발 물질 등과 같은 물리 화학적 요인 등에 의해 기침 및 가래가 발생되며, 이를 치료하기 위해 말초에 있는 신장 수용체(stretch receptor)에 작용하여 기침을 조절하는 말초성 진해제, 베타 2 아고니스트(β2-adrenergic receptor agonist), 점액 용해제 또는 거담제 등이 사용되고 있으나, 기존의 진해 거담제는 부작용과 독성 및 약물 자체의 화학적 불안정성 등으로 인한 문제점을 가지고 있다. As a result, coughing and phlegm are generated by physical and chemical factors such as cold air, external foreign substances including pathogenic microorganisms, air pollutants, and allergens. To treat this, coughing occurs by acting on stretch receptors in the periphery. Peripheral antitussive agents, beta 2 agonists (β2-adrenergic receptor agonists), mucolytics, or expectorants are used to control the condition, but existing antitussive expectorants have problems due to side effects, toxicity, and chemical instability of the drug itself.
이러한 문제를 해결하기 위하여, 최근에는 천연물 유래의 진해거담제 연구가 활발히 진행되고 있으며, 이와 관련한 대표적인 연구로는 기도의 미주신경을 자극하여 점막의 분비를 촉진해 거담작용을 발현함과 동시에 진해작용의 보조적 역할을 하는 사포닌(saponin), 알칼로이드(alkaloid) 등을 함유하는 식물에 관한 보고가 있기도 하지만, 그 성과는 아직 미미한 실정이다.In order to solve this problem, research on antitussive expectorants derived from natural products has been actively conducted in recent years. Representative studies in this regard include stimulating the vagus nerve in the airway to promote secretion of the mucous membrane, thereby producing an expectorant effect and at the same time showing an antitussive effect. There are reports of plants containing saponins and alkaloids that play auxiliary roles, but the results are still minimal.
이에, 본 발명자들은 천연물 유래 호흡기 질환 치료제를 개발하기 위해 노력한 결과, 마가목, 무궁화 및 유근피의 복합추출물이 세포독성이 없고, 유의적인 항염증 효과를 나타내며, 기관지 세포에서 염증성 점액 단백질의 분비를 유의적으로 억제하고, 미세먼지에 의한 호흡기 질환 개선 효과가 있음을 확인하여, 호흡기 질환 예방 또는 치료용 조성물의 유효성분으로 이용할 수 있음을 밝힘으로써, 본 발명을 완성하였다.Accordingly, the present inventors have made efforts to develop a treatment for respiratory diseases derived from natural products, and as a result, the complex extracts of rowan tree, Rose of Sharon and Rhythmia root are non-cytotoxic, exhibit significant anti-inflammatory effects, and significantly reduce the secretion of inflammatory mucus proteins from bronchial cells. The present invention was completed by confirming that it is effective in improving respiratory diseases caused by fine dust and that it can be used as an active ingredient in a composition for preventing or treating respiratory diseases.
따라서, 본 발명의 주된 목적은 세포독성이 없고, 유의적인 항염증 효과를 나타내며, 기관지 세포에서 염증성 점액 단백질의 분비를 유의적으로 억제하고, 미세먼지에 의한 호흡기 질환 개선 효과가 있는 마가목, 무궁화 및 유근피의 3종 식물 복합추출물을 유효성분으로 함유하는 조성물을 제공하는 데 있다.Therefore, the main object of the present invention is rowan tree, Rose of Sharon, and other plants that are non-cytotoxic, exhibit significant anti-inflammatory effects, significantly inhibit the secretion of inflammatory mucus proteins from bronchial cells, and have the effect of improving respiratory diseases caused by fine dust. The aim is to provide a composition containing three types of plant complex extracts of Euderm bark as active ingredients.
본 발명의 다른 목적 및 이점은 하기의 발명의 상세한 설명, 청구범위 및 도면에 의해 보다 명확하게 된다.Other objects and advantages of the present invention will become clearer from the following detailed description, claims, and drawings.
본 발명의 한 양태에 따르면, 본 발명은 마가목, 무궁화 및 유근피의 복합추출물을 유효성분으로 포함하는 호흡기 질환 예방 또는 치료용 약학적 조성물을 제공한다.According to one aspect of the present invention, the present invention provides a pharmaceutical composition for preventing or treating respiratory diseases comprising a complex extract of rowan tree, Rose of Sharon and Rhythmia root bark as an active ingredient.
본 발명에서 상기 "마가목(Sorbus commixta Hedl.)"은 장미과의 잎지는 넓은잎 작은 큰키나무를 의미하며, 본 발명에서는 줄기의 속꽃질(정공피)를 사용한다. 또한, "무궁화(Hibiscus syriacus)"는 쌍떡잎식물 아욱목 아욱과의 낙엽관목을 의미하며, 본 발명에서는 전초, 줄기, 줄기껍질, 꽃, 뿌리 등을 이용할 수 있다. 또한, "유근피"는 느릅나무과 왕느릅나무(Ulmus macrocarpa Hance)의 코르크층을 벗긴 수피를 의미한다. In the present invention, the "Ran ash ( Sorbus commixta Hedl.)" refers to a large tree with broad leaves and small leaves of the Rosaceae family, and in the present invention, the internal flower quality (pore bark) of the stem is used. In addition, " Hibiscus syriacus " refers to a deciduous shrub of the dicotyledonous plant Malvaceae family, and in the present invention, outposts, stems, stem bark, flowers, roots, etc. can be used. In addition, “Ulmus macrocarpa Hance” refers to the bark of Ulmus macrocarpa Hance from which the cork layer has been removed.
본 발명에서 사용되는 용어, "추출물"은 마가목, 무궁화 및 유근피의 추출 처리로 얻어지는 추출액, 상기 추출액의 희석액이나 농축액, 상기 추출액을 건조하여 얻어지는 건조물, 상기 추출액의 조정제물이나 정제물, 또는 이들의 혼합물 등, 추출액 자체 및 추출액을 이용하여 형성 가능한 모든 제형의 추출물을 포함한다. 본 발명의 상기 추출물은 바람직하게 추출 후 건조 분말 형태로 제조되어 사용될 수 있다. As used in the present invention, the term "extract" refers to an extract obtained by extraction treatment of rowan tree, Rose of Sharon, and root bark, a diluted or concentrated liquid of the extract, a dried product obtained by drying the extract, a crude product or purified product of the extract, or a product thereof. This includes extracts such as mixtures, the extract itself, and all formulations that can be formed using the extract. The extract of the present invention can preferably be prepared and used in the form of a dry powder after extraction.
본 발명의 상기 마가목, 무궁화 및 유근피의 추출에 있어서, 상기 추출물을 추출하는 방법은 특별히 제한되지 아니하며, 당해 기술 분야에서 통상적으로 사용하는 방법에 따라 추출할 수 있다. 상기 추출방법의 비제한적인 예로는, 열수 추출법, 초음파 추출법, 여과법, 환류 추출법 등을 들 수 있으며, 이들은 단독으로 수행되거나 2종 이상의 추출방법을 병용하여 수행될 수 있다. In the extraction of the rowan tree, Rose of Sharon, and root bark of the present invention, the method of extracting the extract is not particularly limited, and may be extracted according to a method commonly used in the art. Non-limiting examples of the extraction method include hot water extraction, ultrasonic extraction, filtration, and reflux extraction, which may be performed alone or by combining two or more extraction methods.
본 발명에서 상기 마가목, 무궁화 및 유근피를 추출하는데 사용되는 추출 용매의 종류는 특별히 제한되지 아니하며, 당해 기술 분야에서 공지된 임의의 용매를 사용할 수 있다. 상기 추출 용매의 비제한적인 예로는 물; 메탄올, 에탄올, 프로필알코올, 부틸알코올 등의 탄소수 1 내지 4의 저급 알코올; 글리세린, 부틸렌글리콜, 프로필렌글리콜 등의 다가 알코올; 및 메틸아세테이트, 에틸아세테이트, 아세톤, 벤젠, 헥산, 디에틸에테르, 디클로로메탄 등의 탄화수소계 용매; 또는 이들의 혼합물을 사용할 수 있으며, 바람직하게, 물, 저급알코올, 1,3-부틸렌글리콜, 에틸아세테이트를 단독으로 사용하거나 2종 이상 혼합하여 사용할 수 있다. In the present invention, the type of extraction solvent used to extract the rowan tree, Rose of Sharon and Radicle root bark is not particularly limited, and any solvent known in the art can be used. Non-limiting examples of the extraction solvent include water; lower alcohols having 1 to 4 carbon atoms such as methanol, ethanol, propyl alcohol, and butyl alcohol; Polyhydric alcohols such as glycerin, butylene glycol, and propylene glycol; and hydrocarbon solvents such as methyl acetate, ethyl acetate, acetone, benzene, hexane, diethyl ether, and dichloromethane; Or a mixture thereof can be used, and preferably, water, lower alcohol, 1,3-butylene glycol, and ethyl acetate can be used alone or in a mixture of two or more.
본 발명에서 열수 추출 또는 냉침 추출한 추출물은 부유하는 고체 입자를 제거하기 위해 여과, 예를 들어 나일론 등을 이용해 입자를 걸러내거나 냉동여과법 등을 이용해 여과한 후, 그대로 사용하거나 이를 동결건조, 열풍건조, 분무건조 등을 이용해 건조하여 사용할 수 있다.In the present invention, the extract obtained by hot water extraction or cold immersion extraction is filtered to remove floating solid particles, for example, by filtering the particles using nylon, etc., or by cryofiltration, and then used as is or freeze-dried, hot-air dried, etc. It can be dried and used using spray drying, etc.
본 발명에서 사용되는 용어, "분획물"은 여러 다양한 구성 성분들을 포함하는 혼합물로부터 특정 성분 또는 특정 성분 그룹을 분리하기 위하여 분획을 수행하여 얻어진 결과물을 의미한다.The term “fraction” used in the present invention refers to the result obtained by performing fractionation to separate a specific component or specific component group from a mixture containing various various components.
상기 분획 방법의 비제한적인 예로는, 마가목, 무궁화 및 유근피를 추출하여 얻은 추출물에 소정의 용매를 처리하여 상기 추출물로부터 분획물을 얻는 방법을 들 수 있다. 본 발명에서 상기 분획물을 얻는 데에 사용되는 용매의 종류는 특별히 제한되지 아니하며, 당해 기술 분야에서 공지된 임의의 용매를 사용할 수 있다. 상기 분획 용매의 비제한적인 예로는 물, 알코올 등의 극성 용매; 헥산(Hexane), 에틸아세테이트(Ethyl acetate), 클로로포름(Chloroform), 디클로로메탄(Dichloromethane) 등의 비극성 용매 등을 들 수 있다. 이들은 단독으로 사용되거나 2종 이상 혼합하여 사용될 수 있다. 상기 분획 용매 중 알코올을 사용하는 경우에는 구체적으로는 탄소수 1 내지 4의 알코올을 사용할 수 있다.A non-limiting example of the fractionation method includes a method of obtaining a fraction from the extract obtained by extracting rowan tree, Rose of Sharon and Radix root bark and treating the extract with a predetermined solvent. In the present invention, the type of solvent used to obtain the fraction is not particularly limited, and any solvent known in the art can be used. Non-limiting examples of the fractionating solvent include polar solvents such as water and alcohol; Nonpolar solvents such as hexane, ethyl acetate, chloroform, and dichloromethane may be included. These may be used alone or in combination of two or more types. When alcohol is used among the fractionating solvents, alcohols having 1 to 4 carbon atoms can be specifically used.
본 발명의 호흡기 질환 예방 또는 치료용 약학적 조성물에서, 상기 복합추출물은 이에 제한되는 것은 아니나 마가목, 무궁화 및 유근피 원료를 1 : 0.5-2 : 0.5-2 의 중량비로 혼합하여 추출될 수 있다. In the pharmaceutical composition for preventing or treating respiratory diseases of the present invention, the complex extract is not limited thereto, but can be extracted by mixing rowan tree, Rose of Sharon, and Rhythmia root raw materials at a weight ratio of 1:0.5-2:0.5-2.
본 발명의 호흡기 질환 예방 또는 치료용 약학적 조성물에서, 상기 호흡기 질환은 천식, 기관지염, 폐렴, 기침 또는 가래를 동반하는 폐기종, 기관지 확장증, 폐섬유증 및 만성폐쇄성 폐질환(chronic obstructive pulmonary disease)으로 이루어진 군으로부터 선택되는 어느 하나 이상인 일 수 있으나, 이에 한정되지 않는다.In the pharmaceutical composition for preventing or treating respiratory diseases of the present invention, the respiratory diseases include asthma, bronchitis, pneumonia, emphysema accompanied by cough or phlegm, bronchiectasis, pulmonary fibrosis, and chronic obstructive pulmonary disease. It may be any one or more selected from the group, but is not limited thereto.
본 발명의 호흡기 질환 예방 또는 치료용 약학적 조성물에서, 상기 복합추출물은 염증 매개인자인 일산화질소 생성을 억제하는 것을 특징으로 한다. 본 발명의 바람직한 실시예에서는 마가목, 무궁화 및 유근피의 복합추출물이 이들의 단일추출물에 비해 상승적인 일산화질소 생성 억제 효과(synergy effect)를 나타내며, 100㎍/㎖ 투여군에서는 L-NMMA 처리 양성대조군 대비 일산화질소 생성을 더욱 억제하는 우수한 효과를 확인하였다(도 1 및 도 2 참조). In the pharmaceutical composition for preventing or treating respiratory diseases of the present invention, the complex extract is characterized by inhibiting the production of nitric oxide, an inflammatory mediator. In a preferred embodiment of the present invention, the complex extract of rowan tree, Rose of Sharon and Radix root bark exhibits a synergistic effect of suppressing nitrogen monoxide production compared to their single extracts, and in the 100㎍/㎖ administration group, compared to the L-NMMA treated positive control group, the complex extract shows a synergy effect. An excellent effect of further suppressing nitrogen production was confirmed (see Figures 1 and 2).
본 발명의 호흡기 질환 예방 또는 치료용 약학적 조성물에서, 상기 복합추출물은 미세먼지의 흡입으로 폐 조직에서 유도된 활성산소종 소거 활성을 나타내는 것을 특징으로 한다. 본 발명의 바람직한 실시예에서는 마가목, 무궁화 및 유근피의 복합추출물이 단일추출물에 비해 MH-S 세포의 생존율을 더욱 증가시키고, MH-S 세포 내 활성산소종의 생성을 더욱 효과적으로 감소시키는 것을 확인한 바 있다(도 3 및 도 4 참조). In the pharmaceutical composition for preventing or treating respiratory diseases of the present invention, the complex extract is characterized by exhibiting reactive oxygen species scavenging activity induced in lung tissue by inhalation of fine dust. In a preferred embodiment of the present invention, it has been confirmed that the complex extract of rowan tree, Rose of Sharon and Radix root bark further increases the survival rate of MH-S cells and more effectively reduces the production of reactive oxygen species in MH-S cells compared to the single extract. (See Figures 3 and 4).
본 발명의 호흡기 질환 예방 또는 치료용 약학적 조성물에서, 상기 복합추출물은 염증성 점액단백질인 Mucin 5AC(MUC5AC)의 분비를 억제하는 것을 특징으로 한다. MUC5AC(Mucin 5AC) 단백질은 염증성 점액단백질로, LPS와 같은 물질의 자극으로 분비되고, 이들의 과다분비는 만성폐쇄성 폐질환(chronic obstructive pulmonary disease, COPD)을 유발하는 것으로 잘 알려져 있다. 본 발명의 바람직한 실시예에서는 마가목, 무궁화 및 유근피의 복합추출물이 농도 의존적으로 MUC5AC 분비를 억제하고, 단일추출물에 비해 복합추출물의 MUC5AC 분비 억제 효과가 더욱 우수한 것을 확인한 바 있다(도 5 및 도 6 참조). In the pharmaceutical composition for preventing or treating respiratory diseases of the present invention, the complex extract is characterized by inhibiting the secretion of Mucin 5AC (MUC5AC), an inflammatory mucus protein. MUC5AC (Mucin 5AC) protein is an inflammatory mucus protein that is secreted when stimulated by substances such as LPS, and its hypersecretion is well known to cause chronic obstructive pulmonary disease (COPD). In a preferred embodiment of the present invention, it was confirmed that the complex extract of rowan, Rose of Sharon and Radix root bark inhibits MUC5AC secretion in a concentration-dependent manner, and that the effect of suppressing MUC5AC secretion of the complex extract is more excellent than that of the single extract (see Figures 5 and 6). ).
본 발명에 따른 마가목, 무궁화 및 유근피의 복합추출물은 약학적으로 허용 가능한 염의 형태로 제조될 수 있다. 구체적으로 산을 첨가함으로써 염을 형성할 수 있고, 예를 들어 무기산(예: 염산, 하이드로브롬산, 인산, 질산, 황산 등), 유기 카르복실산(예: 아세트산, 트리플루오로아세트산과 같은 할로 아세트산, 프로피온산, 말레산, 숙신산, 말산, 시트르산, 타르타르산, 살리실산), 및 산성 당(글루쿠론산, 갈락투론산, 글루콘산, 아스코르브산), 산성 폴리사카리드(예: 히알우론산, 콘드로이틴 술페이트, 아르기닌산), 콘드로이틴 설페이트와 같은 술폰산 당 에스테르를 포함하는 유기 술폰산(예: 메탄, 술폰산, p-톨루엔 술폰산) 등을 첨가하여 염을 형성할 수 있다.The complex extract of rowan tree, Rose of Sharon and Radix root bark according to the present invention can be prepared in the form of a pharmaceutically acceptable salt. Specifically, salts can be formed by adding acids, such as inorganic acids (e.g. hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, etc.), organic carboxylic acids (e.g. acetic acid, halo acids such as trifluoroacetic acid). Acetic acid, propionic acid, maleic acid, succinic acid, malic acid, citric acid, tartaric acid, salicylic acid), and acidic sugars (glucuronic acid, galacturonic acid, gluconic acid, ascorbic acid), acidic polysaccharides (e.g. hyaluronic acid, chondroitin sulfate, Salts can be formed by adding organic sulfonic acids (e.g., methane, sulfonic acid, p-toluene sulfonic acid), including sulfonic acid sugar esters such as arginic acid) and chondroitin sulfate.
본 발명에 따른 마가목, 무궁화 및 유근피의 복합추출물은 식용 가능한 식물 성분에서 유래한 물질로, 임상 투여시 경구 또는 비경구로 투여가 가능하며 일반적인 의약품 제제의 형태로 사용될 수 있다. 본 발명의 3종 식물 복합추출물은 실제로 경구 또는 비경구의 여러 가지 제형으로 투여될 수 있는데, 제형화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 비경구투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제가 포함된다. 비수성용제, 현탁용제로는 프로필렌글리콜(Propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 리우린지, 글리세로제라틴 등이 사용될 수 있다.The complex extract of rowan tree, Rose of Sharon and Radix root bark according to the present invention is a substance derived from edible plant ingredients, can be administered orally or parenterally during clinical administration, and can be used in the form of a general pharmaceutical preparation. The complex extract of the three plants of the present invention can actually be administered in various oral or parenteral formulations. When formulated, diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants are used. It is prepared by: Preparations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate. As a base for suppositories, witepsol, macrogol, tween 61, cacao, liuringe, glycerogenatin, etc. can be used.
또한, 본 발명에 따른 마가목, 무궁화 및 유근피의 복합추출물은 생리식염수 또는 유기용매와 같이 약제로 허용된 여러 전달체(carrier)와 혼합하여 사용될 수 있고, 안정성이나 흡수성을 증가시키기 위하여 글루코오스, 수크로오스 또는 덱스트란과 같은 카보하이드레이트, 아스코르브 산(ascorbic acid) 또는 글루타치온과 같은 항산화제(anti-oxidants), 킬레이트화제(chelating agents), 저분자 단백질 또는 다른 안정화제(stabilizers)들이 약제로 사용될 수 있다.In addition, the complex extract of mountain ash, Rose of Sharon and root bark according to the present invention can be used by mixing with various pharmaceutically acceptable carriers such as physiological saline or organic solvents, and can be mixed with glucose, sucrose or dextrose to increase stability or absorption. Carbohydrates such as tran, anti-oxidants such as ascorbic acid or glutathione, chelating agents, low molecular weight proteins or other stabilizers can be used as drugs.
본 발명의 3종 식물 복합추출물의 유효용량은 0.01 내지 10 ㎎/㎏이고, 바람직하게는 0.1 내지 1 ㎎/㎏ 이며, 하루 1회 내지 3회 투여될 수 있다.The effective dose of the complex extract of the three plants of the present invention is 0.01 to 10 mg/kg, preferably 0.1 to 1 mg/kg, and can be administered once to three times a day.
본 발명의 약학적 조성물에서 또는 그 배양액은 총 유효량은 볼루스(bolus) 형태 혹은 상대적으로 짧은 기간 동안 주입(infusion) 등에 의해 단일 투여량(single does)으로 환자에게 투여될 수 있으며, 다중 투여량(multiple does)이 장기간 투여되는 분할 치료 방법(fractionated treatment protocol)에 의해 투여될 수 있다. 상기 농도는 약의 투여 경로 및 치료 횟수뿐만 아니라 환자의 나이 및 건강상태 등 다양한 요인들을 고려하여 환자의 유효 투여량이 결정되는 것이므로 이러한 점을 고려할 때, 이 분야의 통상적인 지식을 가진 자라면 본 발명의 3종 식물 복합추출물의 약학적 조성물로서의 특정한 용도에 따른 적절한 유효 투여량을 결정할 수 있을 것이다.The total effective amount of the pharmaceutical composition of the present invention or its culture medium can be administered to the patient in a single dose, such as in the form of a bolus or by infusion for a relatively short period of time, and can be administered in multiple doses. (multiple does) may be administered by a fractionated treatment protocol in which the drug is administered over a long period of time. The concentration is determined by considering various factors such as the drug administration route and number of treatments as well as the patient's age and health condition. Considering this, those skilled in the art will understand the present invention. It will be possible to determine the appropriate effective dosage according to the specific use as a pharmaceutical composition of the three plant complex extracts.
본 발명의 다른 양태에 따르면, 본 발명은 마가목, 무궁화 및 유근피의 복합추출물을 유효성분으로 포함하는 호흡기 질환 예방 또는 개선용 식품 조성물을 제공한다. 상기 마가목, 무궁화 및 유근피의 3종 식물 복합추출물은 염증 매개인자인 일산화질소 생성을 억제하고, 미세먼지의 흡입에 의해 폐조직에서 유도된 활성산소종 소거활성을 나타내며, 염증성 점액단백질인 Mucin 5AC(MUC5AC)의 분비를 억제하므로 호흡기 질환의 예방 또는 개선을 위한 식품 조성물로 유용하게 사용될 수 있다. 본 발명의 마가목, 무궁화 및 유근피의 복합추출물로 구성된 식물 복합추출물과 이의 호흡기 질환 예방 또는 개선에 대한 효과는 상기에서 설명한 바와 같다. According to another aspect of the present invention, the present invention provides a food composition for preventing or improving respiratory diseases comprising a complex extract of rowan tree, Rose of Sharon and Radix root bark as an active ingredient. The three plant complex extracts of mountain ash, Rose of Sharon, and Radix root bark inhibit the production of nitric oxide, an inflammatory mediator, exhibit reactive oxygen species scavenging activity induced in lung tissue by inhalation of fine dust, and Mucin 5AC (Mucin 5AC), an inflammatory mucus protein. Since it inhibits the secretion of MUC5AC), it can be usefully used as a food composition for preventing or improving respiratory diseases. The plant complex extract consisting of complex extracts of mountain ash, Rose of Sharon and radicle bark of the present invention and its effect on preventing or improving respiratory diseases are as described above.
상기 식품 조성물은 건강기능식품의 형태로 사용될 수 있으나, 이에 제한되는 것은 아니다.The food composition may be used in the form of a health functional food, but is not limited thereto.
본 발명의 식품 조성물은 마가목, 무궁화 및 유근피의 3종 식물 복합추출물과 이들의 가공물의 형태로 포함될 수 있다. 또한, 상기 조성물은 유효성분 이외에 식품학적으로 허용 가능한 식품 보조첨가제를 포함할 수 있다.The food composition of the present invention may be included in the form of complex extracts of three types of plants, such as rowan tree, Rose of Sharon and Rhythmia root bark, and their processed products. Additionally, the composition may include food additives that are foodologically acceptable in addition to the active ingredients.
본 발명에 있어서, "식품 보조첨가제"란 식품에 보조적으로 첨가될 수 있는 구성요소를 의미하며, 각 제형의 건강기능식품을 제조하는데 첨가되는 것으로서 당업자가 적절히 선택하여 사용할 수 있다. 식품 보조첨가제의 예로는 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 충진제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등이 포함되지만, 상기 예들에 의해 본 발명의 식품 보조첨가제의 종류가 제한되는 것은 아니다.In the present invention, "food auxiliary additive" refers to a component that can be added to food as an auxiliary ingredient, and can be appropriately selected and used by a person skilled in the art as it is added to manufacture each type of health functional food. Examples of food auxiliary additives include various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavors, colorants and fillers, pectic acid and its salts, alginic acid and its salts, organic acids, and protective colloidal thickeners. , pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc., but the types of food supplements of the present invention are not limited to the above examples.
본 발명의 식품 조성물에는 건강기능식품이 포함될 수 있다. 본 발명에 있어서, "건강기능식품"이란 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 정제, 캅셀, 분말, 과립, 액상 및 환 등의 형태로 제조 및 가공한 식품을 말한다. 여기서 "기능성"이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건 용도에 유용한 효과를 얻는 것을 의미하며, 본 발명에서는 호흡기 질환의 예방 및 개선을 위한 효과를 얻는 것을 의미한다. 본 발명의 건강기능식품은 당업계에서 통상적으로 사용되는 방법으로 제조 가능하며, 상기 제조시에는 당업계에서 통상적으로 첨가하는 원료 및 성분을 첨가하여 제조할 수 있다.The food composition of the present invention may include health functional foods. In the present invention, “health functional food” refers to food manufactured and processed in the form of tablets, capsules, powders, granules, liquids, and pills using raw materials or ingredients with functional properties useful to the human body. Here, “functionality” means obtaining useful effects for health purposes such as regulating nutrients or physiological effects on the structure and function of the human body, and in the present invention, it means obtaining effects for preventing and improving respiratory diseases. do. The health functional food of the present invention can be manufactured by a method commonly used in the art, and can be manufactured by adding raw materials and components commonly added in the art.
또한, 상기 건강기능식품의 제형 또한 건강기능식품으로 인정되는 제형이면 제한 없이 제조될 수 있다. 본 발명의 식품 조성물은 다양한 형태의 제형으로 제조될 수 있으며, 일반 약품과는 달리 식용 가능한 식물 성분을 원료로 하여 식품의 장기 복용 시 발생할 수 있는 부작용 등이 없는 장점이 있고, 휴대성이 뛰어나며, 호흡기 및 염증 질환의 예방 및 개선 효과를 증진시키는 보조제로 섭취할 수 있다.Additionally, the formulation of the health functional food can also be manufactured without limitation as long as it is a formulation recognized as a health functional food. The food composition of the present invention can be manufactured in a variety of formulations, and unlike general drugs, it is made from edible plant ingredients, so it has the advantage of having no side effects that may occur when taking food for a long period of time, and is highly portable. It can be taken as a supplement to improve the prevention and improvement of respiratory and inflammatory diseases.
본 발명의 건강기능식품이 취할 수 있는 형태에는 제한이 없으며, 통상적인 의미의 식품을 모두 포함할 수 있고, 기능성 식품 등 당업계에 알려진 용어와 혼용하여 사용할 수 있다. 아울러 본 발명의 건강기능식품은 당업자의 선택에 따라 식품에 포함될 수 있는 적절한 기타 보조 성분과 공지의 첨가제를 혼합하여 제조할 수 있다. 첨가할 수 있는 식품의 예로는 육류, 소세지, 빵, 초콜릿, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알코올 음료 및 비타민 복합제 등이 있으며, 본 발명에 따른 마가목, 무궁화 및 유근피의 3종 식물 복합추출물을 주성분으로 하여 제조한 즙, 차, 젤리 및 주스 등에 첨가하여 제조할 수 있다. 또한, 동물을 위한 사료로 이용되는 식품도 포함된다.There is no limit to the form that the health functional food of the present invention can take, and it can include all foods in the conventional sense, and can be used interchangeably with terms known in the art, such as functional food. In addition, the health functional food of the present invention can be manufactured by mixing known additives with other appropriate auxiliary ingredients that can be included in the food according to the selection of a person skilled in the art. Examples of foods that can be added include meat, sausages, bread, chocolate, candies, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, and There are vitamin complexes, etc., and they can be prepared by adding them to juices, teas, jellies, juices, etc. prepared using the complex extracts of three types of plants, rowan tree, Rose of Sharon, and radicle bark according to the present invention, as main ingredients. It also includes foods used as feed for animals.
본 발명은 마가목, 무궁화 및 유근피의 3종 식물 복합추출물을 유효성분으로 함유하는 호흡기 질환의 예방, 치료 및 개선용 조성물을 제공한다.The present invention provides a composition for preventing, treating and improving respiratory diseases containing complex extracts of three types of plants, rowan tree, Rose of Sharon and Rhythmia root, as active ingredients.
본 발명에 따른 마가목, 무궁화 및 유근피의 3종 식물 복합추출물은 염증 매개인자인 일산화질소 생성을 억제하고, 미세먼지의 흡입에 의해 폐조직에서 유도된 활성산소종 소거 활성을 나타내고, 염증성 점액단백질인 Mucin 5AC(MUC5AC)의 분비를 억제하므로 호흡기 질환의 예방, 개선 및 치료 용도로 식품 및 의약 분야에 유용하게 활용될 수 있다. The complex extract of three types of plants of rowan, Rose of Sharon and Rhythmia root according to the present invention suppresses the production of nitric oxide, an inflammatory mediator, exhibits reactive oxygen species scavenging activity induced in lung tissue by inhalation of fine dust, and removes inflammatory mucus protein. Because it inhibits the secretion of Mucin 5AC (MUC5AC), it can be useful in the food and pharmaceutical fields for the prevention, improvement, and treatment of respiratory diseases.
도 1은 마가목, 무궁화 및 유근피의 단일 또는 복합추출물을 RAW 264.7 세포에 처리한 후, 세포 생존율의 변화를 측정하여 나타낸 그래프이다.
도 2는 마가목, 무궁화 및 유근피의 단일 또는 복합추출물을 RAW 264.7 세포에 처리한 후, 일산화질소 생성량을 측정하여 나타낸 그래프이다.
도 3은 마가목, 무궁화 및 유근피의 단일 또는 복합추출물을 MH-S 세포에 처리한 후, 세포 생존율의 변화를 측정하여 나타낸 그래프이다.
도 4는 마가목, 무궁화 및 유근피의 단일 또는 복합추출물을 MH-S 세포에 처리한 후, 활성산소종의 생성량 변화를 측정하여 나타낸 그래프이다.
도 5는 마가목, 무궁화 및 유근피의 단일 또는 복합추출물을 인간 유래 기관지 상피세포주인 NCI-H292 세포에 처리한 후, 세포 생존율의 변화를 측정하여 나타낸 그래프이다.
도 6은 마가목, 무궁화 및 유근피의 단일 또는 복합추출물을 인간 유래 기관지 상피세포주인 NCI-H292 세포에 처리한 후, 염증성 점액단백질인 MUC5AC(Mucin 5AC)의 생성량 변화를 측정하여 나타낸 그래프이다. Figure 1 is a graph showing the change in cell viability after treating RAW 264.7 cells with single or complex extracts of rowan, Rose of Sharon, and Rhythmia root bark.
Figure 2 is a graph showing the amount of nitrogen monoxide produced after treating RAW 264.7 cells with single or complex extracts of rowan, Rose of Sharon, and Rhythmia root bark.
Figure 3 is a graph showing the change in cell viability after treating MH-S cells with single or complex extracts of rowan tree, Rose of Sharon, and Rhythmia root bark.
Figure 4 is a graph showing the change in production of reactive oxygen species after treating MH-S cells with single or complex extracts of rowan tree, Rose of Sharon, and Rhythmia root bark.
Figure 5 is a graph showing the change in cell viability after treatment with single or complex extracts of rowan, Rose of Sharon, and Rhythmia root bark on NCI-H292 cells, a human-derived bronchial epithelial cell line.
Figure 6 is a graph showing the change in production of MUC5AC (Mucin 5AC), an inflammatory mucus protein, after treating single or complex extracts of rowan, Rose of Sharon, and Rhythmia root to NCI-H292 cells, a human-derived bronchial epithelial cell line.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하기로 한다. 이들 실시예는 단지 본 발명을 예시하기 위한 것이므로, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지는 않는다.Hereinafter, the present invention will be described in more detail through examples. Since these examples are merely for illustrating the present invention, the scope of the present invention is not to be construed as limited by these examples.
실시예 1. 식물 추출물의 제조Example 1. Preparation of plant extract
1-1. 마가목 추출물의 제조1-1. Preparation of rowan extract
건조 중량 100g의 분쇄한 마가목 분말을 10배 중량의 정제수로 12시간 가온 환류추출하고 냉침한 후, 1.2㎛ 투과 사이즈를 갖는 여과지(Glassfiber, sartorius, 미국)로 여과하였다. 이 여과된 추출액을 50℃ 이하에서 감압농축한 후 감압건조기(Eyela Rotary evaporator, Tokyo Rikakika Co.,LTD, 일본)를 이용해 완전히 건조시켜 마가목 추출물(제조예 1)을 수득하였다.A dry weight of 100 g of pulverized mountain ash powder was refluxed and extracted with 10 times the weight of purified water for 12 hours, cooled, and then filtered through filter paper (Glassfiber, sartorius, USA) with a penetration size of 1.2 ㎛. The filtered extract was concentrated under reduced pressure below 50°C and then completely dried using a reduced pressure dryer (Eyela Rotary evaporator, Tokyo Rikakika Co., LTD, Japan) to obtain a rowan extract (Preparation Example 1).
1-2. 무궁화 추출물의 제조1-2. Preparation of Rose of Sharon extract
마가목 분말을 무궁화 분말로 대체한 것을 제외하고 실시예 1-1과 동일한 방법을 사용하여, 무궁화 추출물(제조예 2)을 수득하였다.Rose of Sharon extract (Preparation Example 2) was obtained using the same method as Example 1-1, except that rowan tree powder was replaced with Rose of Sharon powder.
1-3. 유근피 추출물의 제조1-3. Preparation of root bark extract
마가목 분말을 유근피 분말로 대체한 것을 제외하고 실시예 1-1과 동일한 방법을 사용하여, 유근피 추출물(제조예 3)을 수득하였다.A derm bark extract (Preparation Example 3) was obtained using the same method as Example 1-1, except that rowan tree powder was replaced with root bark powder.
1-4. 3종 식물 복합추출물의 제조1-4. Manufacturing of 3 types of plant complex extracts
마가목 분말을 대체하여 마가목, 무궁화 및 유근피 분말이 1:1:1의 중량비율로 혼합된 혼합 분말을 사용한 것을 제외하고 실시예 1-1과 동일한 방법을 사용하여, 3종 복합추출물(제조예 4)을 수득하였다.Using the same method as Example 1-1, except that instead of rowan powder, a mixed powder of rowan tree, Rose of Sharon, and root bark powder mixed at a weight ratio of 1:1:1 was used, three types of composite extracts (Preparation Example 4 ) was obtained.
실시예 2. 항염증 활성Example 2. Anti-inflammatory activity
2-1. 세포 독성2-1. cytotoxicity
마가목, 무궁화 및 유근피의 단일추출물 또는 이들의 복합추출물이 대식세포주인 RAW 264.7 세포의 생장에 미치는 효과를 아래와 같은 방법으로 확인하였다. 실험은 대식세포주인 RAW 264.7 세포를 한국세포주은행(KTCC, Seoul, Korea)에서 분양받아 사용하였고, 10% FBS(Fetal bovine serum)를 함유한 DMEM(Dulbecco’s modified Eagle’s medium)에 10% FBS, 100㎍/㎖ 페니실린 및 100㎍/㎖ 스트렙토마이신을 첨가한 배지에 상기 세포를 접종하여 37℃, 5% CO2 조건에서 배양하였다.The effect of single extracts of rowan tree, Rose of Sharon and Radix root bark or their complex extracts on the growth of RAW 264.7 cells, a macrophage cell line, was confirmed by the following method. In the experiment, RAW 264.7 cells, a macrophage cell line, were purchased from the Korea Cell Line Bank (KTCC, Seoul, Korea), and 10% FBS (100 μg) was added to DMEM (Dulbecco's modified Eagle's medium) containing 10% FBS (Fetal bovine serum). The cells were inoculated into a medium containing 100 ㎍/㎖ penicillin and 100㎍/㎖ streptomycin and cultured at 37°C and 5% CO 2 conditions.
상기 RAW 264.7 세포를 1×106 cells/mL 농도(in DMEM)로 96웰 플레이트에 접종하고 24시간 배양한 후, 실시예 1에서 제조된 마가목, 무궁화 및 유근피의 단일추출물(제조예 1 내지 3)과 이들의 복합추출물(제조예 4)을 10, 50, 및 100㎍/㎖ 농도로 희석한 시료와 내독소로 알려진 LPS(1μg/ml)를 함유한 새로운 배지를 동시에 처리하여 24시간 배양하였다. 배양 후, 1mg/mL의 MTT 시약을 처리하고 2시간이 경과한 후, MTT 처리로 인해 생성된 포마잔(formazan)을 DMSO 용매로 녹여 570nm에서 흡광도를 측정하였다. The RAW 264.7 cells were inoculated into a 96-well plate at a concentration of 1 × 10 6 cells/mL (in DMEM) and cultured for 24 hours, and then the single extracts of rowan tree, Rose of Sharon and Rhythmia bark prepared in Example 1 (Preparation Examples 1 to 3 ) and their complex extract (Preparation Example 4) were treated simultaneously with samples diluted to concentrations of 10, 50, and 100 μg/ml and new medium containing LPS (1 μg/ml), a known endotoxin, and cultured for 24 hours. . After incubation, 1 mg/mL of MTT reagent was treated, and after 2 hours, formazan produced by MTT treatment was dissolved in DMSO solvent and absorbance was measured at 570 nm.
실험 결과, RAW 264.7 세포에 마가목, 무궁화 및 유근피의 단일추출물 또는 이들의 복합추출물을 처리한 경우, 마가목, 무궁화 및 유근피의 단일추출물 또는 이들의 복합추출물이 농도의존적으로 RAW 264.7 세포의 세포 생존율을 증가시키는 것으로 확인되었고, 이를 통해 마가목, 무궁화 및 유근피의 단일추출물 또는 이들의 복합추출물이 인체에 독성을 나타내지 않고, 오히려 세포 생존을 크게 증가시키는 것을 확인할 수 있었다(도 1 참조).As a result of the experiment, when RAW 264.7 cells were treated with single extracts of rowan, Rose of Sharon, and radicle bark or their complex extracts, the single extracts of rowan, Rose of Sharon, and radicle root bark or their complex extracts increased the cell survival rate of RAW 264.7 cells in a concentration-dependent manner. It was confirmed that single extracts of rowan tree, Rose of Sharon and Radix root bark or their complex extracts do not exhibit toxicity to the human body, but rather significantly increase cell survival (see Figure 1).
2-1. NO 생성 억제2-1. Inhibition of NO production
마가목, 무궁화 및 유근피의 단일추출물 또는 이들의 복합추출물이 갖는 일산화질소(nitric oxide, NO) 생성 억제 효과를 측정하였다. 일산화질소는 염증 유발에 관여하는 대표적인 세포 독성물질이다. The inhibitory effect on nitric oxide (NO) production of single extracts or complex extracts of rowan tree, Rose of Sharon and Radix root bark was measured. Nitric oxide is a representative cytotoxic substance involved in causing inflammation.
대식세포주인 RAW 264.7 세포는 실시예 2-1과 동일한 방법으로 배양하였고, 실시예 1에서 제조한 3종 식물체의 단일추출물 또는 이들의 복합추출물을 10, 50, 및 100㎍/㎖ 농도로 희석한 시료와 내독소로 알려진 LPS(1μg/ml)를 함유한 새로운 배지를 동시에 처리하여 24시간 배양하였다. 그 후, 세포배양 상등액 100㎕와 Griess reagent[1%(w/v) sulfanilamide, 0.1%(w/v) naphtylethylenediamine in 2.5%(v/v) phosphoric acid] 100㎕를 혼합하여 96 well 플레이트에서 10분 동안 반응시켰다. RAW 264.7 cells, a macrophage cell line, were cultured in the same manner as in Example 2-1, and single extracts or complex extracts of the three plants prepared in Example 1 were diluted to concentrations of 10, 50, and 100 μg/ml. The samples were simultaneously treated with new medium containing LPS (1 μg/ml), a known endotoxin, and cultured for 24 hours. Afterwards, 100 ㎕ of cell culture supernatant and 100 ㎕ of Griess reagent [1% (w/v) sulfanilamide, 0.1% (w/v) naphtylethylenediamine in 2.5% (v/v) phosphoric acid] were mixed and cultured in 10 well plates. Reacted for minutes.
상기 Griess reagent 반응 후, ELISA 리더를 사용하여 540nm에서 흡광도를 측정하여 생성된 산화질소의 양을 측정하였다. 생성된 아질산염(nitrite)의 농도는 아질산나트륨(sodium nitrite)을 DMEM 용액에 용해한 표준 곡선을 이용하여 계산하였다. 비교실험을 위해 NO 생성 억제제로 알려진 L-NMMA(NG-Methyl-L-arginine, acetate salt, 50nM)을 양성대조군으로 사용하였다. After the Griess reagent reaction, the amount of nitric oxide produced was measured by measuring absorbance at 540 nm using an ELISA reader. The concentration of nitrite produced was calculated using a standard curve of sodium nitrite dissolved in DMEM solution. For the comparative experiment, L-NMMA (N G -Methyl-L-arginine, acetate salt, 50nM), known as an inhibitor of NO production, was used as a positive control.
실험 결과를 정리한 [도 2]를 참조하면, LPS 처리군(Con)에 비해 3종 식물의 단일추출물(제조예 1 내지 3)을 시료로 처리한 시험군 모두에서 일산화질소의 생성량이 농도 의존적으로 감소하는 양상을 확인할 수 있었고, 마가목, 유근피, 무궁화의 순으로 일산화질소의 생성 억제능이 우수한 것으로 확인되었다.Referring to [Figure 2], which summarizes the experimental results, compared to the LPS-treated group (Con), the amount of nitrogen monoxide produced in all test groups treated with single extracts of three plants (Preparation Examples 1 to 3) was concentration-dependent. A decreasing trend was confirmed, and it was confirmed that the ability to suppress the production of nitrogen monoxide was excellent in the order of rowan ash, radicle root bark, and Rose of Sharon.
또한, 마가목, 무궁화 및 유근피의 복합추출물(제조예 4)이 이들의 단일추출물에 비해 상승적인 일산화질소 생성 억제 효과(synergy effect)를 보였으며, 100㎍/㎖ 투여군에서는 L-NMMA 처리 양성대조군 대비 더욱 우수한 일산화질소 생성 억제 효과를 나타내는 것으로 관찰되었고, 3종 성분 조합에 따른 시너지 활성이 관찰되었다. In addition, the complex extract of rowan tree, Rose of Sharon and Radix root bark (Preparation Example 4) showed a synergy effect to suppress nitrogen monoxide production compared to their single extracts, and in the 100㎍/㎖ administered group, compared to the L-NMMA treated positive control group. It was observed to have a better effect of suppressing nitric oxide production, and synergistic activity was observed according to the combination of the three ingredients.
실시예 3. 미세먼지 노출 세포 모델에서 활성산소종 생성 억제 활성Example 3. Inhibitory activity of reactive oxygen species production in fine dust exposed cell model
미세먼지 환경에서 마가목, 무궁화 및 유근피의 단일추출물 또는 이들의 복합추출물의 활성산소종 감소 활성을 측정하였다. The reactive oxygen species reduction activity of single extracts or complex extracts of mountain ash, Rose of Sharon, and Rhythmia root bark was measured in a fine dust environment.
폐포 대식세포(alveolar macrophages)로 알려진 MH-S(CRL-2019. ATCC, Manassas, VA, USA) 세포는 10% fetal bovine serum(FBS, Gibco, Grand Island, NY, USA) 및 1% penicillin-streptonycin solution(PS, Gibco)을 첨가한 RPMI 1640(complete medium) 배지를 넣어 37℃, 5% CO2 조건에서 배양하였다. 디젤 분진에 의해 유도된 초미세먼지(fine particulate matter, PM) 환경에서 본 발명의 3종 복합 추출물의 활성산소종(ROS, reactive oxygen species) 생성 감소 효과를 확인하기 위해서, MH-S 세포를 최종 농도가 1x105 cell/well이 되도록 96 well 플레이트에 200㎕ 부피로 분주하였다. 24 시간 경과 후에 전체 배지를 제거하고, 세럼 프리 RPMI 1640 배지 200㎕로 교체하였다. 실험군은 세럼 프리 RPMI 1640 배지로 교체하고 2시간 경과 후 무궁화, 마가목, 및 유근피의 단일 또는 복합추출물을 각각 10, 50, 및 100㎍/㎖ 농도로 첨가하고, 24시간 동안 37℃, 5% CO2 조건에서 배양하였다. 한편, 0.05% tween 80 함유한 생리식염수에 최종 2㎎/㎖의 디젤분진을 첨가하여 용액을 준비하고, 이를 20분간 초음파(sonication)를 가하여 분진상태로 제조한 후, 상기 24시간 배양된 세포에 디젤분진 100㎍/㎖를 처리하여(약 200㎕ well 당 5㎕씩) 제작하였다. 음성대조군은 아무것도 처리하지 않고 실험군과 동일하게 배양된 MH-S 세포를 사용하였다. 또한, 디젤분진 투여군은 0.05% tween 80 함유한 생리식염수에 최종 2㎎/㎖의 디젤분진을 첨가하여 용액을 준비하고, 이를 20분간 초음파(sonication)를 가하여 분진상태로 제조한 후, 상기 24시간 배양된 세포에 디젤분진 100㎍/㎖를 처리하여(약 200㎕ well 당 5㎕씩) 제작하였다. 디젤분진을 처리하고 3시간 후 세포를 회수하였다. MH-S (CRL-2019. ATCC, Manassas, VA, USA) cells, known as alveolar macrophages, were incubated with 10% fetal bovine serum (FBS, Gibco, Grand Island, NY, USA) and 1% penicillin-streptonycin. RPMI 1640 (complete medium) medium supplemented with solution (PS, Gibco) was added and cultured at 37°C and 5% CO 2 conditions. In order to confirm the effect of the three complex extracts of the present invention on reducing the production of reactive oxygen species (ROS) in the fine particulate matter (PM) environment induced by diesel dust, MH-S cells were finalized. A volume of 200 ㎕ was dispensed into a 96 well plate so that the concentration was 1x10 5 cell/well. After 24 hours, the entire medium was removed and replaced with 200 μl of serum-free RPMI 1640 medium. In the experimental group, the medium was replaced with serum-free RPMI 1640, and after 2 hours, single or complex extracts of Rose of Sharon, Rowan, and Radix root bark were added at concentrations of 10, 50, and 100㎍/㎖, respectively, and incubated at 37℃, 5% CO for 24 hours. Cultured under 2 conditions. Meanwhile, a final solution of 2 mg/ml of diesel dust was added to physiological saline containing 0.05% tween 80 to prepare a solution, which was prepared into a dust state by applying sonication for 20 minutes, and then added to the cells cultured for 24 hours. It was produced by treating 100㎍/㎖ of diesel dust (5㎕ per approximately 200㎕ well). The negative control group used MH-S cells cultured in the same way as the experimental group without any treatment. In addition, the diesel dust administration group prepared a solution by adding a final 2 mg/mL of diesel dust to physiological saline containing 0.05% tween 80, prepared it in a dust state by applying sonication for 20 minutes, and incubated the solution for 24 hours. Cultured cells were prepared by treating 100㎍/㎖ of diesel dust (approximately 5㎕ per 200㎕ well). Cells were recovered 3 hours after treatment with diesel dust.
각 실험군으로부터 활성산소종 측정을 위해 회수한 세포를 PBS로 2번 세척하고, RPMI 1640 배지에 2',7'-dichlorodihydrofluorescein diacetate(DCFDA, Thermo)를 10uM 농도로 준비한 후, 이를 각 well에 200㎕씩 분주하고, 30분 동안 37℃ 및 5% CO2 조건에서 배양하였다. 배양이 완료된 후 세포를 다시금 PBS로 2회 세척하였고, 컴플리트 배지(Complete medium)에 혼합하여 제조한 3.7% 포르말린 용액을 15분 동안 처리하여 37℃ 및 5% CO2 조건에서 고정하였다. PBS 용액을 100㎕ 분주하고, micro-plate reader 기기로 흡수파장 495㎚, 방출파장 529㎚에서 DCFDA 형광발광을 검출 및 정량하여 세포 내 활성산소종 생성량을 분석하였다. Cells recovered from each experimental group to measure reactive oxygen species were washed twice with PBS, and 2',7'-dichlorodihydrofluorescein diacetate (DCFDA, Thermo) was prepared in RPMI 1640 medium at a concentration of 10uM, and then 200㎕ of this was added to each well. They were dispensed into portions and incubated at 37°C and 5% CO 2 for 30 minutes. After the culture was completed, the cells were again washed twice with PBS, treated with a 3.7% formalin solution prepared by mixing with Complete medium for 15 minutes, and fixed at 37°C and 5% CO 2 conditions. 100 μl of the PBS solution was dispensed, and DCFDA fluorescence was detected and quantified at an absorption wavelength of 495 nm and an emission wavelength of 529 nm using a micro-plate reader device to analyze the amount of reactive oxygen species produced within the cells.
먼저, 폐포 대식세포인 MH-S 세포의 생존율을 정리한 [도 3]을 참조하면, 초미세먼지 환경 조건에서 MH-S 세포에 대한 독성이 확인되었으나, 마가목, 무궁화 및 유근피의 단일추출물 첨가는 MH-S 세포 증식을 증가시키는 것으로 분석되었다. 또한, 마가목, 무궁화 및 유근피의 복합추출물은 이들의 단일추출물에 비해 MH-S 세포에 독성이 없으며 오히려 세포의 증식을 더욱 현저하게 증가시키는 것으로 분석되었다. First, referring to [Figure 3], which summarizes the survival rate of MH-S cells, which are alveolar macrophages, toxicity to MH-S cells was confirmed under ultrafine dust environmental conditions, but the addition of single extracts of rowan tree, Rose of Sharon and Rhythmia root bark was confirmed. It was analyzed to increase MH-S cell proliferation. In addition, it was analyzed that complex extracts of mountain ash, Rose of Sharon, and Radix root bark were not toxic to MH-S cells compared to their single extracts, but rather significantly increased cell proliferation.
또한, 폐포 대식세포인 MH-S 세포의 활성산소종 생성량을 정리한 [도 4]를 참조하면, 초미세먼지 환경 조건에서 MH-S 세포 내 활성산소종의 생성량이 2배 정도 증가하고, 마가목, 무궁화 및 유근피의 단일추출물 첨가는 MH-S 세포 내 활성산소종 생성을 유의하게 감소시키는 것으로 분석되었다. 또한, 3종 성분의 복합추출물은 이들의 단일추출물에 비해 MH-S 세포 내 활성산소종의 생성을 더욱 감소시키는 것으로 분석되었고, 3종 성분 조합에 따른 시너지 활성이 관찰되었다. In addition, referring to [Figure 4], which summarizes the amount of reactive oxygen species produced by MH-S cells, which are alveolar macrophages, the amount of reactive oxygen species produced within MH-S cells increases by about 2-fold under ultrafine dust environmental conditions, and , it was analyzed that the addition of single extracts of Rose of Sharon and Radix root bark significantly reduced the production of reactive oxygen species in MH-S cells. In addition, the complex extract of the three components was analyzed to further reduce the production of reactive oxygen species in MH-S cells compared to their single extract, and synergistic activity was observed according to the combination of the three components.
실시예 4. 인간 기관지 상피세포 보호 및 MUC5AC 분비 억제 활성Example 4. Protective activity of human bronchial epithelial cells and inhibition of MUC5AC secretion
4-1. 기관지 상피세포 보호 활성4-1. Bronchial epithelial cell protective activity
마가목, 무궁화 및 유근피의 단일추출물 또는 이들의 복합추출물의 기관지 상피세포에 대한 보호 활성을 시험하였다. The protective activity of single extracts of rowan tree, Rose of Sharon, and Rhizoma root bark or their complex extracts on bronchial epithelial cells was tested.
상기 실시예 1에서 준비한 마가목, 무궁화 및 유근피의 단일추출물 또는 이들의 복합추출물을 인간 기관지 상피세포인 MH-S 세포에 처리하고 LPS 및 PMA(phorbol 12- myristate 13-acetate)로 MUC5AC 분비를 유도하고, 기관지 상피세포의 세포 생존율을 분석하였다. MH-S cells, which are human bronchial epithelial cells, were treated with single extracts of mountain ash, Rose of Sharon, and radicle bark prepared in Example 1 or their complex extracts, and MUC5AC secretion was induced with LPS and PMA (phorbol 12-myristate 13-acetate). , the cell survival rate of bronchial epithelial cells was analyzed.
구체적으로, 기관지 상피세포는 인간 유래 기관지 상피세포주인 NCI-H292 세포를 4×104 세포/㎖로 24-웰 플레이트에 500㎕씩 분주하였고, 37℃ 및 5% CO2 조건의 배양기에서 48시간 동안 배양하여 세포를 안정화했다. 48 시간 뒤 배양 배지를 모두 제거하였고, 0.2% FBS/DMEM 배지로 교체한 후 24시간 동안 배양하였다. 배양된 세포를 PBS 용매로 2번 세척하였고, 무혈청 배지 400㎕와 농도별로 희석한 마가목, 무궁화 및 유근피의 단일추출물 또는 이들의 복합추출물을 각각 10, 50, 및 100㎍/㎖ 농도로 첨가하고 1시간 동안 배양하였다. 이후, 100ng/㎖ 농도의 PMA 및 20㎍/㎖ 농도의 LPS를 처리하고 24시간 동안 재배양하여 MUC5AC 단백질의 생성을 유도하고, NCI-H292 세포의 생존율을 측정하였다. Specifically, the bronchial epithelial cells were NCI-H292 cells, a human-derived bronchial epithelial cell line, dispensed at 4 × 10 4 cells/ml in 500 ㎕ each in a 24-well plate, and incubated in an incubator at 37°C and 5% CO 2 for 48 hours. The cells were stabilized by culturing for a while. After 48 hours, all culture medium was removed, replaced with 0.2% FBS/DMEM medium, and cultured for 24 hours. The cultured cells were washed twice with PBS solvent, and 400 ㎕ of serum-free medium and single extracts or complex extracts of rowan, Rose of Sharon, and Rhythmia root diluted by concentration were added at concentrations of 10, 50, and 100 ㎍/㎖, respectively. Incubated for 1 hour. Afterwards, the cells were treated with PMA at a concentration of 100 ng/ml and LPS at a concentration of 20 μg/ml and re-cultured for 24 hours to induce the production of MUC5AC protein, and the survival rate of NCI-H292 cells was measured.
실험 결과를 정리한 [도 5]를 참조하면, LPS 및 PMA만을 처리한 시료 무처리군과 비교하여, LPS 및 PMA와 함께 마가목, 무궁화 또는 유근피의 단일추출물 시료를 처리한 시험군에서는 낮은 농도에서 NCI-H292 세포 생존율 증가가 관찰되었으나, NCI-H292 세포 생존율 증가 효과가 미미한 것으로 나타났다. 반면, 마가목, 무궁화 및 유근피의 3종 복합추출물은 NCI-H292 세포의 생존율을 농도 의존적으로 증가시키는 것으로 나타났는데, 이들 3종 성분 추출물 처리군은 LPS 및 PMA 처리군 대비 NCI-H292 세포의 생존율이 각각 102%(10㎍/㎖), 108%(50㎍/㎖) 및 112%(100㎍/㎖) 증가하여 각각의 단일추출물 처리군에 비해 인간 기관지 세포 보호에 효과적인 것으로 확인되었고, 3종 성분 조합에 따른 시너지 활성이 관찰되었다. Referring to [Figure 5], which summarizes the experimental results, compared to the untreated group of samples treated only with LPS and PMA, the test group treated with single extract samples of rowan tree, Rose of Sharon or radicle bark along with LPS and PMA had lower concentrations. An increase in NCI-H292 cell survival rate was observed, but the effect of increasing NCI-H292 cell survival rate was found to be minimal. On the other hand, the three complex extracts of rowan tree, Rose of Sharon and Radix root bark were found to increase the survival rate of NCI-H292 cells in a concentration-dependent manner, and the survival rate of NCI-H292 cells in the group treated with these three component extracts was lower than the group treated with LPS and PMA. It was confirmed to be effective in protecting human bronchial cells compared to the single extract treatment group, increasing by 102% (10㎍/㎖), 108% (50㎍/㎖), and 112% (100㎍/㎖), respectively. Synergistic activity was observed depending on the combination.
4-2. 염증성 점액 단백질 분비 억제 활성4-2. Inhibitory activity of inflammatory mucus protein secretion
MUC5AC(Mucin 5AC) 단백질은 염증성 점액단백질로, LPS와 같은 물질의 자극에 의해 분비되고, 이들의 과다분비는 만성폐쇄성 폐질환(chronic obstructive pulmonary disease, COPD)을 유발하는 것으로 알려져 있다. 이에, 기관지 상피세포에서 마가목, 무궁화 및 유근피의 단일추출물 또는 이들의 복합추출물의 MUC5AC 억제 활성을 알아보기 위하여, 상기 마가목, 무궁화 및 유근피의 단일추출물 또는 이들의 복합추출물을 농도별로 처리하고 LPS 및 PMA로 MUC5AC 분비를 유도한 기관지 상피세포에서 MUC5AC의 분비량을 sandwitch ELISA 방법을 이용하여 분석하였다. MUC5AC (Mucin 5AC) protein is an inflammatory mucus protein that is secreted upon stimulation by substances such as LPS, and its hypersecretion is known to cause chronic obstructive pulmonary disease (COPD). Therefore, in order to investigate the MUC5AC inhibitory activity of single extracts of Rowan, Rose of Sharon, and Rhythmia root bark or their complex extracts in bronchial epithelial cells, single extracts of Rowan, Rose of Sharon, and Rhythmia root bark or their complex extracts were treated at different concentrations, and LPS and PMA The amount of MUC5AC secretion from bronchial epithelial cells that induced MUC5AC secretion was analyzed using the sandwitch ELISA method.
세포 배양 및 MUC5AC 생성 유도는 상기 실시예 4-1의 방법과 동일한 방법을 사용하였고, sandwitch ELISA 방법은 LSBio KIT를 제조사 프로토콜을 이용하여 분석하였다. Cell culture and MUC5AC production induction were performed using the same method as in Example 4-1, and the sandwitch ELISA method was analyzed using LSBio KIT according to the manufacturer's protocol.
실험 결과를 정리한 [도 6]을 참조하면, LPS 및 PMA만을 처리한 시료 무처리군과 비교하여, LPS 및 PMA와 함께 마가목, 무궁화 및 유근피의 단일추출물 또는 이들의 복합추출물을 처리한 시험군에서는 농도 의존적으로 MUC5AC 분비를 억제하는 것으로 관찰되었는데, 단일추출물에 비해 복합추출물의 MUC5AC 분비 억제 효과가 더욱 우수한 것으로 분석되었다. Referring to [Figure 6], which summarizes the experimental results, compared to the untreated group treated only with LPS and PMA, the test group treated with single extracts of rowan tree, Rose of Sharon, and radicle root bark or their complex extracts along with LPS and PMA. It was observed to inhibit MUC5AC secretion in a concentration-dependent manner, and the effect of inhibiting MUC5AC secretion of the complex extract was found to be better than that of the single extract.
구체적으로 LPS 및 PMA 처리군 대비 마가목 단일추출물 처리군은 12%(10㎍/㎖), 24%(50㎍/㎖) 및 32%(100㎍/㎖) 감소한 MUC5AC 분비량이 측정되었고, 무궁화 단일추출물 처리군은 3%(10㎍/㎖), 10%(50㎍/㎖) 및 19%(100㎍/㎖) 감소한 MUC5AC 분비량이 측정되었으며, 유근피 단일추출물 처리군은 4%(10㎍/㎖), 13%(50㎍/㎖) 및 22%(100㎍/㎖) 감소한 MUC5AC 분비량이 측정되었다. 이에 반해 이들의 3종 복합추출물 처리군에서는 28%(10㎍/㎖), 44%(50㎍/㎖) 및 68%(100㎍/㎖) 감소한 MUC5AC 분비량이 측정되어 각각의 단일추출물 처리군에 비해 MUC5AC 분비 감소에 효과적인 것으로 확인되었고, 3종 성분 조합에 따른 시너지 활성이 관찰되었다. Specifically, compared to the LPS and PMA treated groups, the MUC5AC secretion amount was measured to be reduced by 12% (10㎍/㎖), 24% (50㎍/㎖), and 32% (100㎍/㎖) in the group treated with the rowan extract, and the group treated with the Rose of Sharon single extract. In the treatment group, MUC5AC secretion decreased by 3% (10㎍/㎖), 10% (50㎍/㎖), and 19% (100㎍/㎖), and in the group treated with the root bark single extract, it decreased by 4% (10㎍/㎖). , MUC5AC secretion decreased by 13% (50 μg/ml) and 22% (100 μg/ml) was measured. On the other hand, in the three complex extract treatment groups, MUC5AC secretion decreased by 28% (10㎍/㎖), 44% (50㎍/㎖), and 68% (100㎍/㎖) were measured, showing that each single extract treatment group It was confirmed to be effective in reducing MUC5AC secretion, and synergistic activity was observed according to the combination of the three ingredients.
이상으로 본 발명의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적인 기술은 단지 바람직한 구현예일 뿐이며, 이에 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다.As the specific parts of the present invention have been described in detail above, it is clear to those skilled in the art that these specific techniques are merely preferred embodiments and do not limit the scope of the present invention.
따라서, 본 발명의 실질적인 범위는 첨부된 청구항과 그의 등가물에 의하여 정의된다고 할 것이다.Accordingly, the substantial scope of the present invention will be defined by the appended claims and their equivalents.
Claims (7)
상기 복합추출물은 마가목, 무궁화 및 유근피 원료를 1 : 0.5-2 : 0.5-2의 중량비로 혼합하여 추출된 것을 특징으로 하는, 호흡기 질환 예방 또는 치료용 약학적 조성물.According to paragraph 1,
The complex extract is a pharmaceutical composition for preventing or treating respiratory diseases, characterized in that it is extracted by mixing rowan tree, Rose of Sharon and Radix root bark raw materials at a weight ratio of 1:0.5-2:0.5-2.
상기 호흡기 질환은 천식, 기관지염, 폐렴, 기침 또는 가래를 동반하는 폐기종, 기관지 확장증, 폐섬유증 및 만성폐쇄성 폐질환(chronic obstructive pulmonary disease)으로 이루어진 군으로부터 선택되는 어느 하나 이상인 것을 특징으로 하는, 호흡기 질환 예방 또는 치료용 약학적 조성물.According to paragraph 1,
The respiratory disease is characterized in that at least one selected from the group consisting of asthma, bronchitis, pneumonia, emphysema accompanied by cough or phlegm, bronchiectasis, pulmonary fibrosis, and chronic obstructive pulmonary disease. Pharmaceutical composition for prevention or treatment.
상기 복합추출물은 염증 매개인자인 일산화질소 생성을 억제하는 것을 특징으로 하는, 호흡기 질환 예방 또는 치료용 약학적 조성물. According to paragraph 1,
The complex extract is a pharmaceutical composition for preventing or treating respiratory diseases, characterized in that it inhibits the production of nitric oxide, an inflammatory mediator.
상기 복합추출물은 미세먼지의 흡입으로 폐 조직에서 유도된 활성산소종 소거 활성을 나타내는 것을 특징으로 하는, 호흡기 질환 예방 또는 치료용 약학적 조성물. According to paragraph 1,
The complex extract is a pharmaceutical composition for preventing or treating respiratory diseases, characterized in that it exhibits reactive oxygen species scavenging activity induced in lung tissue by inhalation of fine dust.
상기 복합추출물은 염증성 점액단백질인 Mucin 5AC(MUC5AC)의 분비를 억제하는 것을 특징으로 하는, 호흡기 질환 예방 또는 치료용 약학적 조성물. According to paragraph 1,
The complex extract is a pharmaceutical composition for preventing or treating respiratory diseases, characterized in that it inhibits the secretion of Mucin 5AC (MUC5AC), an inflammatory mucus protein.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020220172745A KR20240087242A (en) | 2022-12-12 | 2022-12-12 | Composition for Prevention or Treatment Respiratory Diseases Comprising Combination Extracts of Sorbus commixta, Hibiscus syriacus and Ulmus macrocarpa as an Active Ingredient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020220172745A KR20240087242A (en) | 2022-12-12 | 2022-12-12 | Composition for Prevention or Treatment Respiratory Diseases Comprising Combination Extracts of Sorbus commixta, Hibiscus syriacus and Ulmus macrocarpa as an Active Ingredient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240087242A true KR20240087242A (en) | 2024-06-19 |
Family
ID=91713163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020220172745A KR20240087242A (en) | 2022-12-12 | 2022-12-12 | Composition for Prevention or Treatment Respiratory Diseases Comprising Combination Extracts of Sorbus commixta, Hibiscus syriacus and Ulmus macrocarpa as an Active Ingredient |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20240087242A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190043997A (en) | 2017-10-19 | 2019-04-29 | 종근당건강 주식회사 | Composition for prevention or treatment respiratory diseases comprising combination extracts of Chrysanthemum morifolium Ramatuelle and Scutellaria baicalensis as an active ingredient |
| KR20200027451A (en) | 2018-09-04 | 2020-03-12 | 한국식품연구원 | Composition for improving respiratory diseases using the extract of Camellia sinensis |
-
2022
- 2022-12-12 KR KR1020220172745A patent/KR20240087242A/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190043997A (en) | 2017-10-19 | 2019-04-29 | 종근당건강 주식회사 | Composition for prevention or treatment respiratory diseases comprising combination extracts of Chrysanthemum morifolium Ramatuelle and Scutellaria baicalensis as an active ingredient |
| KR20200027451A (en) | 2018-09-04 | 2020-03-12 | 한국식품연구원 | Composition for improving respiratory diseases using the extract of Camellia sinensis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102173159B1 (en) | Antiviral Composition Against Influenza Virus, Composition for Treating Respiratory Disease, and Anti-Aging Composition Containing Extract of Black Ginseng | |
| Vyawahare et al. | Phoenix dactylifera: An update of its indegenous uses, phytochemistry and pharmacology | |
| KR20120133133A (en) | Composition for Prevention or Treatment of Respiratory Disease Comprising Herbal Extract and Fermentation Product thereof with Lactic acid Bacteria | |
| KR101647029B1 (en) | Pharmaceutical composition for preventing or treating chronic obstructive pulmonary diseases(COPD), comprising an extract, a fraction or a compounds derived from Pistacia weinmannifolia | |
| KR102134385B1 (en) | Composition for Respiratory Symptoms Containing Red Ginseng Extract | |
| KR102252126B1 (en) | Composition for prevention or treatment respiratory diseases comprising combination extracts of Chrysanthemum morifolium Ramatuelle and Scutellaria baicalensis as an active ingredient | |
| KR101397841B1 (en) | Composition for Prevention or Treatment of Inflammatory Pulmonary Diseases Comprising Alisma orientale extract | |
| KR20180011021A (en) | Pharmaceutical composition comprising extract of Clematis apiifolia DC. or Silene armeria L. for treating or prventing inflammatory disease | |
| KR20190109220A (en) | Herbal Composition for Preventing or Treating Respiratory Disease | |
| McCalla et al. | Physiologic effects of Hibiscus sabdariffa (Sorrel) on biological systems: Advances in Sorrel research | |
| KR20170054116A (en) | A pharmaceutical composition comprising extract from germinated gemmule of bean for preventing or treating obesity | |
| KR20240087242A (en) | Composition for Prevention or Treatment Respiratory Diseases Comprising Combination Extracts of Sorbus commixta, Hibiscus syriacus and Ulmus macrocarpa as an Active Ingredient | |
| KR20150063905A (en) | Compositions for preventing or improving of alcoholic liver disease, or reducing alcoholic hangup comprising Rosa rugosa extracts | |
| Younus et al. | Antioxidant, analgesic and anti-inflammatory activities of in vitro and field-grown Iceberg lettuce extracts | |
| KR20180006612A (en) | Compositions for preventing or treating diabetes mellitus comprising extract of Aster koraiensis or fraction thereof | |
| KR20150072660A (en) | Hepatoprotective composition containing adenophora triphylla extract | |
| KR20240033710A (en) | Composition for Prevention and Treatment of Cough, Sputum, and Bronchial Disease as an Active Ingredient | |
| KR20230014156A (en) | Composition for Anti-Obesity Comprising Catechin, and Complex Extracts of Rosa davurica Pall as Active Ingredient | |
| KR101296075B1 (en) | Novel use of extract of callophyllis japonica | |
| Sharma et al. | The chemical composition and pharmaceutical effect of celosia cristata: a review on nutritional aspect | |
| KR20210100302A (en) | Phamaceutical composition for prevetion or treatment of a respiratory disease with extract of Rubus coreanus Miquel fruits | |
| KR102355104B1 (en) | Pharmaceutical and functional food composition comprising complex extract of Brassica rapa for prevention or treatment of respiratory disease | |
| KR20210143967A (en) | Composition for preventing, improving or treating respiratory disease | |
| KR101711397B1 (en) | Pharmaceutical compositions and health functional foods comprising Persicaria fauriei extracts for preventing or treating anticancer agent-induced of hematopoietic toxicity | |
| KR102355106B1 (en) | Pharmaceutical and functional food composition comprising complex extract of Platycodon grandiflorus for prevention or treatment of respiratory disease |